Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359

Roy M. Gulick, X. Joan Hu, Susan A. Fiscus, Courtney V. Fletcher, Richard Haubrich, Hailong Cheng, Edward Acosta, Stephen W. Lagakos, Ronald Swanstrom, William Freimuth, Sally Snyder, Charlotte Mills, Margaret Fischl, Carla Pettinelli, David Katzenstein

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

This study compared antiretroviral activity among 6 'salvage' therapy regimens. The study was a prospective, randomized, 2 x 3 factorial, multicenter study of the AIDS Clinical Trials Group. The study enrolled 277 human immunodeficiency virus (HIV)-infected patients naive to nonnucleoside analogues who had taken indinavir >6 months. The patients had 2000-200,000 HIV RNA copies/mL. Patients received saquinavir with ritonavir or nelfinavir together with delavirdine and/or adefovir and were followed for safety and antiretroviral response between baseline and week 16. At week 16, 30% (77/254) of patients had ≤500 HIV RNA copies/mL. Virologic response did not differ significantly between pooled ritonavir and nelfinavir groups (28% vs. 33%; P =. 50) or between pooled delavirdine and delavirdine/adefovir groups (40% vs. 33%; P =. 42). Pooled delavirdine groups had a greater virologic response rate than did adefovir groups (40% vs. 18%; P =. 002). Overall, one-third of patients who experienced virologic failure on an indinavir-containing regimen suppressed virus load levels while they were taking a new salvage regimen.

Original languageEnglish (US)
Pages (from-to)1375-1384
Number of pages10
JournalJournal of Infectious Diseases
Volume182
Issue number5
DOIs
StatePublished - Jan 1 2000

Fingerprint

Delavirdine
Nelfinavir
Saquinavir
Indinavir
Ritonavir
Acquired Immunodeficiency Syndrome
Clinical Trials
HIV
RNA
Salvage Therapy
Multicenter Studies
adefovir
Viruses
Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir : AIDS Clinical Trials Group study 359. / Gulick, Roy M.; Hu, X. Joan; Fiscus, Susan A.; Fletcher, Courtney V.; Haubrich, Richard; Cheng, Hailong; Acosta, Edward; Lagakos, Stephen W.; Swanstrom, Ronald; Freimuth, William; Snyder, Sally; Mills, Charlotte; Fischl, Margaret; Pettinelli, Carla; Katzenstein, David.

In: Journal of Infectious Diseases, Vol. 182, No. 5, 01.01.2000, p. 1375-1384.

Research output: Contribution to journalArticle

Gulick, RM, Hu, XJ, Fiscus, SA, Fletcher, CV, Haubrich, R, Cheng, H, Acosta, E, Lagakos, SW, Swanstrom, R, Freimuth, W, Snyder, S, Mills, C, Fischl, M, Pettinelli, C & Katzenstein, D 2000, 'Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359', Journal of Infectious Diseases, vol. 182, no. 5, pp. 1375-1384. https://doi.org/10.1086/315867
Gulick, Roy M. ; Hu, X. Joan ; Fiscus, Susan A. ; Fletcher, Courtney V. ; Haubrich, Richard ; Cheng, Hailong ; Acosta, Edward ; Lagakos, Stephen W. ; Swanstrom, Ronald ; Freimuth, William ; Snyder, Sally ; Mills, Charlotte ; Fischl, Margaret ; Pettinelli, Carla ; Katzenstein, David. / Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir : AIDS Clinical Trials Group study 359. In: Journal of Infectious Diseases. 2000 ; Vol. 182, No. 5. pp. 1375-1384.
@article{44c8024c8fe3438d8ba7b516fd810ffb,
title = "Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359",
abstract = "This study compared antiretroviral activity among 6 'salvage' therapy regimens. The study was a prospective, randomized, 2 x 3 factorial, multicenter study of the AIDS Clinical Trials Group. The study enrolled 277 human immunodeficiency virus (HIV)-infected patients naive to nonnucleoside analogues who had taken indinavir >6 months. The patients had 2000-200,000 HIV RNA copies/mL. Patients received saquinavir with ritonavir or nelfinavir together with delavirdine and/or adefovir and were followed for safety and antiretroviral response between baseline and week 16. At week 16, 30{\%} (77/254) of patients had ≤500 HIV RNA copies/mL. Virologic response did not differ significantly between pooled ritonavir and nelfinavir groups (28{\%} vs. 33{\%}; P =. 50) or between pooled delavirdine and delavirdine/adefovir groups (40{\%} vs. 33{\%}; P =. 42). Pooled delavirdine groups had a greater virologic response rate than did adefovir groups (40{\%} vs. 18{\%}; P =. 002). Overall, one-third of patients who experienced virologic failure on an indinavir-containing regimen suppressed virus load levels while they were taking a new salvage regimen.",
author = "Gulick, {Roy M.} and Hu, {X. Joan} and Fiscus, {Susan A.} and Fletcher, {Courtney V.} and Richard Haubrich and Hailong Cheng and Edward Acosta and Lagakos, {Stephen W.} and Ronald Swanstrom and William Freimuth and Sally Snyder and Charlotte Mills and Margaret Fischl and Carla Pettinelli and David Katzenstein",
year = "2000",
month = "1",
day = "1",
doi = "10.1086/315867",
language = "English (US)",
volume = "182",
pages = "1375--1384",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir

T2 - AIDS Clinical Trials Group study 359

AU - Gulick, Roy M.

AU - Hu, X. Joan

AU - Fiscus, Susan A.

AU - Fletcher, Courtney V.

AU - Haubrich, Richard

AU - Cheng, Hailong

AU - Acosta, Edward

AU - Lagakos, Stephen W.

AU - Swanstrom, Ronald

AU - Freimuth, William

AU - Snyder, Sally

AU - Mills, Charlotte

AU - Fischl, Margaret

AU - Pettinelli, Carla

AU - Katzenstein, David

PY - 2000/1/1

Y1 - 2000/1/1

N2 - This study compared antiretroviral activity among 6 'salvage' therapy regimens. The study was a prospective, randomized, 2 x 3 factorial, multicenter study of the AIDS Clinical Trials Group. The study enrolled 277 human immunodeficiency virus (HIV)-infected patients naive to nonnucleoside analogues who had taken indinavir >6 months. The patients had 2000-200,000 HIV RNA copies/mL. Patients received saquinavir with ritonavir or nelfinavir together with delavirdine and/or adefovir and were followed for safety and antiretroviral response between baseline and week 16. At week 16, 30% (77/254) of patients had ≤500 HIV RNA copies/mL. Virologic response did not differ significantly between pooled ritonavir and nelfinavir groups (28% vs. 33%; P =. 50) or between pooled delavirdine and delavirdine/adefovir groups (40% vs. 33%; P =. 42). Pooled delavirdine groups had a greater virologic response rate than did adefovir groups (40% vs. 18%; P =. 002). Overall, one-third of patients who experienced virologic failure on an indinavir-containing regimen suppressed virus load levels while they were taking a new salvage regimen.

AB - This study compared antiretroviral activity among 6 'salvage' therapy regimens. The study was a prospective, randomized, 2 x 3 factorial, multicenter study of the AIDS Clinical Trials Group. The study enrolled 277 human immunodeficiency virus (HIV)-infected patients naive to nonnucleoside analogues who had taken indinavir >6 months. The patients had 2000-200,000 HIV RNA copies/mL. Patients received saquinavir with ritonavir or nelfinavir together with delavirdine and/or adefovir and were followed for safety and antiretroviral response between baseline and week 16. At week 16, 30% (77/254) of patients had ≤500 HIV RNA copies/mL. Virologic response did not differ significantly between pooled ritonavir and nelfinavir groups (28% vs. 33%; P =. 50) or between pooled delavirdine and delavirdine/adefovir groups (40% vs. 33%; P =. 42). Pooled delavirdine groups had a greater virologic response rate than did adefovir groups (40% vs. 18%; P =. 002). Overall, one-third of patients who experienced virologic failure on an indinavir-containing regimen suppressed virus load levels while they were taking a new salvage regimen.

UR - http://www.scopus.com/inward/record.url?scp=0033794231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033794231&partnerID=8YFLogxK

U2 - 10.1086/315867

DO - 10.1086/315867

M3 - Article

C2 - 11023461

AN - SCOPUS:0033794231

VL - 182

SP - 1375

EP - 1384

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -